Encapsulated lanthanum strontium manganese oxide in mesoporous silica shell: Potential for cancer treatment by hyperthermia therapy

Add time:08/18/2019    Source:sciencedirect.com

We have reported the synthesis of core-shell nanostructure of mesoporous silica coated lanthanum strontium manganese oxide nanoparticles (MSLN) as a potential candidate for cancer treatment via magnetic hyperthermia. N2 adsorption-desorption isotherm revealed that mesoporous silica shell coating increased the surface area and pore volume of lanthanum strontium manganese oxide nanoparticles (LSMO). In comparison to LSMO, MSLN showed a stable colloidal dispersion up to 48 h. In-vitro studies using A549 cells demonstrated increased biocompatibility in MSLN as compared to LSMO. Moreover, cells treated with MSLN exhibited high cell survival rate of up to 1 mg/ml concentration. Further, we used different parameters to modulate the heating efficacies of these nanoparticles. The modulation of specific absorption rates (SAR) with different sample concentrations (0.5, 1, 1.5, 2.0 mg/ml) were studied under four different alternating current magnetic field (AMF) amplitudes (10, 11, 12, 13 kA/m) at a constant frequency of 335 KHz for magnetic hyperthermia experiments. Under the application of AMF, MSLN exhibited faster Néel and Brownian relaxation compared to their LSMO counterparts. SAR value of 295 W/g and intrinsic loss power (ILP) of 5.22 nHm2/kg, at a low sample concentration of MSLN (0.5 mg/ml) were obtained, which was within the clinical limit. Interestingly, our results showed 45% improvement in terms of the heating efficiency over the commercially available products (Table 3). Hence, we conclude that MSLN with high SAR and ILP values, good colloidal dispersion ability and low cytotoxicity could be a potential candidate for magnetic hyperthermia therapy in cancer and warrant further testing in both in-vitro and in-vivo studies. Further, due to their mesoporous nature, MSLN could be considered for target-specific drug delivery applications in clinical therapy.

We also recommend Trading Suppliers and Manufacturers of STRONTIUM OXIDE (cas 1314-11-0). Pls Click Website Link as below: cas 1314-11-0 suppliers

Prev:Positive modulation of osteogenesis on a titanium oxide surface incorporating STRONTIUM OXIDE (cas 1314-11-0): An in vitro and in vivo study
Next:Original articleIncreased serum strontium levels and altered oxidative stress status in early-onset preeclampsia)